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Abstract
Human rhinovirus (HRV) infections are associated with the common cold, occasionally with more serious lower respiratory
tract illnesses, and frequently with asthma exacerbations. The clinical features of HRV infection and its association with
asthma exacerbation suggest that some HRV disease results from virus-induced host immune responses to infection. To
study the HRV-infection-induced host responses and the contribution of these responses to disease, we have developed an
in vitro model of HRV infection of human airway epithelial cells (Calu-3 cells) and subsequent exposure of human peripheral
blood mononuclear cells (PBMCs) to these infected cells in a two-chamber trans-well tissue culture system. Using this
model, we studied HRV 14 (species B) and HRV 16 (species A) induced cytokine and chemokine responses with PBMCs from
four healthy adults. Infection of Calu-3 cells with either virus induced HRV-associated increases in FGF-Basic, IL-15, IL-6, IL-
28A, ENA-78 and IP-10. The addition of PBMCs to HRV 14-infected cells gave significant increases in MIP-1b, IL-28A, MCP-2,
and IFN-a as compared with mock-infected cells. Interestingly, ENA-78 levels were reduced in HRV 14 infected cells that
were exposed to PBMCs. Addition of PBMCs to HRV 16-infected cells did not induce MIP-1b, IL-28A and IFN-a efficiently nor
did it decrease ENA-78 levels. Our results demonstrate a clear difference between HRV 14 and HRV 16 and the source of
PBMCs, in up or down regulation of several cytokines including those that are linked to airway inflammation. Such
differences might be one of the reasons for variation in disease associated with different HRV species including variation in
their link to asthma exacerbations as suggested by other studies. Further study of immune responses associated with
different HRVs and PBMCs from different patient groups, and the mechanisms leading to these differences, should help
characterize pathogenesis of HRV disease and generate novel approaches to its treatment.
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Introduction
Human rhinoviruses (HRVs) belong to the genus Enterovirus in
the family Picornaviridae. They are small, non-enveloped, positive
strand RNA viruses with a diameter of about 30 nm. There are
well over 100 serotypes (or genotypes) of HRVs, phylogenetically
divided into three species, A, B, and C. Species A and B viruses
can be divided into two receptor binding groups, major and
minor. The major group uses inter-cellular adhesion molecule 1
(ICAM1) or CD54 as its receptor (90% of species A and B HRVs)
and the minor group uses low-density lipoprotein as its receptor
[1,2,3]. The receptor for species C HRVs has not yet been
identified, but is thought to be distinct. HRVs are the predominant
cause of common cold. However, HRV infection also causes lower
respiratory tract disease including bronchitis, bronchiolitis and
pneumonia [4], and is associated with wheezing and asthma
exacerbations in children and adults [5,6,7]. These studies
demonstrate that HRV infection is commonly associated with
asthma exacerbations, i.e. detected in 50% to 80% of patients with
exacerbations, and it is likely that the HRV-induced host response
to infection is important to these exacerbations. Hence, studying
this response should provide insight into pathogenesis of HRV
disease including exacerbations of asthma.
We chose to study the human response to HRV infection by
modeling local infection with respiratory epithelial cells, the
primary site of human infection, and modeling the immune
response to this infection with peripheral blood mononuclear cells
(PBMCs). Previously, various respiratory epithelial cells have been
used to study the response to HRV infection in vitro and have
shown that HRV infection induces a variety of chemokines and
cytokines (eg. IL-1, IL-6, IL-8, ENA-78, eotaxin, RANTES and
Gro-a) [8,9,10,11,12,13,14,15]. Some of these cytokines and
chemokines have been associated with asthma [5,6]. Other
investigators have also studied the response of PBMCs, or cells
purified from PBMCs, to HRV infection and showed a significant
increase in cytokines and chemokines such as IP-10 and IFN-a
[8,9].
In our model, we used a two-chamber trans-well tissue culture
system to expose the PBMCs to the HRV-infected airway
epithelial cells. With this two-chamber trans-well system, cell
contact that might induce HLA-associated responses that
confound our results is prevented, but virus, virus antigens and
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cellular proteins such as cytokines and chemokines can cross the
membrane. Thus, this system allows ‘‘cross-talk’’ between the
airway epithelial cells and the PBMCs. With this system, we can
assess the response associated with different airway epithelial cells,
different strains of HRV, or different sources of PBMCs. In this
report, we used a constant source of airway epithelial cells, i.e. a
continuous cell line, and studied differences between strains of
HRV and source of PBMCs. We used production of cytokines and
chemokines as an indicator of the response to the infection.
Methods
Ethics statement
The individuals in this manuscript have given written informed
consent to participate in this study and to publish these case
details. The PBMCs had been isolated from blood samples
collected from four healthy adults under an Emory Institutional
Review Board approved protocol (IRB #-00045690).
Human Airway Epithelial Cells (HAEC) and Viruses
Calu-3, A549 and BEAS-2B cells were obtained from American
Type Culture Collection (ATCC) and grown in minimum essential
medium (MEM) supplemented with 10% fetal calf serum (FCS),
1 mM L- Glutamine, 1 mM Hepes and 1X non-essential amino
acids (Calu-3 media) and incubated at 37uC under 5% CO2. HRV
14 and HRV 16 prototype strains were obtained from the Centers
for Disease Control and Prevention (Dr. Dean Erdman). The
viruses were grown in HeLa cells maintained in MEM containing
10% FCS, 1% penicillin streptomycin and 1% L-Glutamine at
35uC under 5% CO2. We chose to study HRV 14 (species B) and
HRV 16 (species A), both major receptor group viruses, because
they are commonly used for in vitro infection studies. HRV C
could not be evaluated in the study because of the difficulty in
cultivating the virus. HRV 14 and HRV 16 stocks were prepared
by infecting monolayers of HeLa cells. The infected cells were
maintained at 35uC under 5% CO2 until cytopathic effect (CPE)
exceeded 70%. The media was collected and centrifuged briefly to
remove the cellular debris, and the clear supernatant was divided
into aliquots and stored at –80uC.
To determine the virus titer, Hela cells were grown in 96 well
flat bottom tissue culture plates (5000 cells/well) and infected with
10-fold serial dilutions of virus in 8 replicates. The infected cells
were incubated for 5 days and evaluated daily for CPE by
microscopic examination. The tissue culture infectivity dose
(TCID50) of the viruses was calculated based on the CPE
according to the Reed Muench method. To assess replication of
the virus in the human respiratory epithelial cell lines, 150,000
cells/well were seeded in 24 well plates and incubated at 37uC
under 5% CO2. When the cells reached 60% confluency, they
were infected with 0.5 MOI of HRV 14 and HRV 16, and the
course of infection assessed at 35uC under 5% CO2. Two days
post infection, the media was changed. Supernatants from virus
infected wells and control wells were collected daily to assess levels
of viral RNA. The collected media were briefly centrifuged to
remove the cell debris and RNA was extracted using Qiagen
RNEasy mini kit according to manufacturer’s instructions. HRV
RNA was assayed by a real-time RT-PCR assay using AgPath-
IDTM One-Step RT-PCR Reagents and the Applied Biosystems
7500 Fast Real-Time PCR System (Life Technologies Corpora-
tion, Carlsbad, CA) as previously described [16]. The time course
of HRV 14 and HRV 16 replication in Calu-3 cells (i.e. gradual
increase in virus RNA and gradual increase in CPE through 5
days post infection), was best suited to our studies and hence Calu-
3 cells were used for the remaining studies. Infection was less
efficient in BEAS-2B cells and CPE was extensive by 24 to 48 hrs
in A549 cells (data not shown).
HAEC and PBMC Co-culture
For the cytokine and chemokine studies, Calu-3 cells were
seeded and infected as mentioned above with 0.5 MOI of
infectious virus, heat-inactivated virus, and mock-infected cell
control material. The inoculum was removed 2 hours later and
500 ul of Calu-3 media was added to each well. Heat-inactivated
viruses were prepared by incubating the viruses at 58uC for one
hour. The media was removed and fresh media was added two
days post infection (p.i.). One day later, i.e. 3 days p.i., trans-well
inserts (polyester trans-well inserts, 0.33 cm with 0.4u pores,
Corning, Inc., Corning, NY) with one million live PBMCs
(viability determined by trypan blue exclusion) were placed in
the virus infected and control wells. PBMCs were purified from the
blood using ficoll-histopaque density gradient centrifugation,
divided into aliquots, and stored in liquid nitrogen. We chose
cryopreserved cells because they are often used for PBMC studies
and provide a consistent source of cells. A consistent source of cells
facilitates comparisons between experiments. Media was collected
from the basolateral chamber at 6, 24, and 48 hours after addition
of the PBMCs. The collected media was centrifuged, stored at –
80uC, and later tested by multiplex luminex assays according to
the manufacturer’s instructions for FGF-Basic, IFN-c, IL–12
(p40/p70), IL–13, RANTES, MIP–1a, MIG, MIP–1b, VEGF,
IL–1b, IL–2, IL–4, IL–5, IL–6, IL–2R, MCP–1, Eotaxin, IL–8,
IL–10, IL–15, IL–17, IL–1RA, GM–CSF, G–CSF, EGF, HGF,
TNF-a, IL–7, IP-10, IFN-a (Human cytokine 30-plex panel, Life
technologies), 6Ckine, BCA-1, CTACK, ENA-78, Eotaxin-2,
Eotaxin-3, I-309, IL-16, IL-20, IL-21, IL-23, IL-28A, IL-33,
LIF, MCP-2, MCP-4, MIP-1d, SCF, SDF-1A+b, TARC, TPO,
TRAIL, TSLP (Human cytokine 23 plex panel, Millipore) and
ENA-78, TSLP and IL-33 (Human cytokine 3 plex panel,
Millipore).
Analysis
Statistical analyses were conducted using SAS 9.2 (Cary, NC)
and statistical significance was assessed at the 0.05 unless otherwise
noted. Due to the small sample sizes and non-normal data,
nonparametric tests were utilized. Specifically, for each cytokine,
the actual data values were replaced by their rank in the dataset
and the analyses were carried out on the ranked data. The median
and range were used to summarize cytokine levels. We initially
looked for cytokine and chemokines that had a significant increase,
or decrease, with HRV infection both without and with PBMCs.
In this analysis, the values for HRV-infected cells (for each HRV
14 and 16 independently) were compared to values for mock
infected cells and the values for PBMCs exposed to infected cells
compared to values for PBMCs exposed to mock infected cells.
The cytokines that showed a significant increase or decrease (i.e.
an HRV-associated response) were analyzed further using a two-
factor analysis of variance model (ANOVA). With this model, we
assessed the effect of the addition of PBMCs and virus type
(HRV14/HRV16) on results. All models initially included a term
for interactions between PBMC and virus type but this term was
removed from the model if the effect was not significant.
Specifically, we compared the effect of virus type on cytokine
expression for different sources of PBMCs, and the effect of
PBMCs on cytokine expression for each virus type. For most
analyses, we compared: (1) HRV-14- without PBMC (N) vs. HRV-
16- N PBMCs, (2) HRV-14- with PBMCs (Y) vs. HRV-16-Y
PBMC, (3) HRV-14- N PBMC vs. HRV-14-Y PBMC and (4)
HRV-16- N PBMC vs. HRV-16- Y PBMC. To control for multiple
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comparisons, a Bonferroni adjustment was used and statistical
significance was assessed using a significance level of 0.05/
4 = 0.0125.
Results
The replication kinetics based on real-time RT-PCR Ct values
varied between the viruses (Fig 1A) with HRV 14 growing more
efficiently than HRV 16. Infectivity titrations on supernatants of
the Calu-3 infected cells, similar to results for RT-PCR, showed
gradual increase in infectious virus over time and more efficient
replication for HRV 14 (data not shown).
As noted in earlier studies, a number of chemokines and
cytokines were induced by HRV infection of airway epithelial
cells. Not previously described, however, are the types of
differences in responses between HRV 14 and HRV 16 and the
impact of adding PBMCs on responses to infection. Initially we
looked at the cytokine/chemokine secretion at 1, 2, 3, 4, and 5
days p.i without the addition of PBMCs. We saw substantially
lower levels of cytokines and chemokines (often not significantly
above mock infected levels) at 1 and 2 days p.i (data not shown)
and consistent increases above mock infected levels at 3, 4, and 5
days p.i. Peak levels were often achieved at 4 or 5 days post
infection. Hence, we focused our analysis on days 3–5 p.i. Virus or
cellular proteins in the inoculum should not have been present at 3
days p.i. since the inoculum was removed 2 hrs post infection and
the media was changed 2 days p.i. Since the levels of cytokines/
chemokines induced by heat inactivated (HI) HRV control or
mock-infected control inoculum were similar, we used mock-
infected control for most comparisons. HRV-associated change in
the levels, i.e. difference between HRV-infected compared to
mock infected cells at 3-5 days p.i was noted for IL-6, IL-15, MIP-
1b, IL-28A, interferon gamma-induced protein 10 (IP-10 or
CXCL10), epithelial neutrophil activation protein-78 (ENA-78),
and basic fibroblast growth factor (FGF-Basic) without PBMCs
(Table 1). In addition, differences in responses induced by HRV
14 compared to HRV 16 infected cells were evident for ENA-78,
Figure 1. Time course of replication and cytokine production in HRV 14 and HRV 16 infected Calu-3 cells. Fig 1A. The relative amount
of viral RNA detected in supernatants of Calu-3 cells infected with 0.5 MOI of HRV 14 or HRV 16 in real time (RT) PCR and represented as inverse cycle
threshold (Ct) values. Ct levels reflect the number of cycles required to exceed the background level; inverse Ct levels (1/Ct) are proportional to the
amount of target nucleic acid in the sample. RT-PCR underwent 40 cycles of amplification. The data are represented as average 6 SD from a
representative experiment. Fig 1B, 1C, 1D, 1E and 1F. Levels of cytokines (pg/ml) in the supernatant of Calu-3 cells infected with HRV 14 or
HRV 16, heat inactivated (HI) viruses and uninfected control (con) cells with or without PBMCs. The 6, 24 and 48 hour time points represent hours
after the time inserts with PBMCs were added to the Calu-3 cells. Data are average 6 SD from duplicate wells for one experiment that is
representative of the four experiments.
doi:10.1371/journal.pone.0066600.g001
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FGF-Basic, IL-6, IP-10, MIP-1b, IFN-a, MCP-2 and IL-28A,
(Table 1).
The addition of PBMCs to the infected cells affected results for
some but not all cytokines. For the cytokines FGF basic and IL-15
the addition of PBMCs did not significantly change the levels
(Table 1) and for IL-6 the addition of PBMCs did not affect the
relative differences between the levels associated with HRV 14 and
HRV 16 infection. Hence PBMCs were removed from ANOVA
model for these three cytokines/chemokines. HRV 16 produced
higher levels of FGF-basic compared to HRV 14 [(median values -
157.2 pg/ml vs.57.1 pg/ml) (p,0.001)]. There was no significant
difference in IL-15 levels between the two viruses [(530.7 pg/ml
vs. 425.6 pg/ml) (p = 0.228)]. HRV 16 produced higher levels of
IL-6 compared to the HRV-14 virus [(2490 pg/ml vs. 1263 pg/
ml) (p = 0.018)] and the addition of PBMCs significantly decreased
IL-6 expression for both viruses (p,0.001). For the other cytokines
and chemokines the PBMCs did affect results and PBMCs were
included in the model (Table 2). HRV 14 produced higher levels
of IP-10 compared to HRV 16 for both with and without PBMCs
(p = 0.003 and p,0.001, respectively) (Table 2). The addition of
PBMCs significantly decreased IP-10 expression in HRV 14
(p = 0.012); but not in HRV 16 infections (p = 0.163) (Table 2).
Without PBMCs, HRV 16 produced significantly higher levels of
MIP-1b compared to HRV 14 (p = 0.003); however, when PBMCs
were added, HRV 14 produced significantly higher levels of MIP-
1b compared to HRV 16 (p = 0.003). The addition of PBMCs
significantly increased MIP-1b expression in HRV 14 infected
cells (p,0.001), whereas PBMCs had no effect on MIP-1b
expression in the HRV 16 virus (p = 0.502) (Table 2, Fig 1F).
Without PBMCs, there was no difference in IFN-a expression
by HRV serotype (p = 0.502) (Table 2, Fig 1B). After the addition
of PBMCs, HRV 14 produced higher levels of IFN-a (Table 2, Fig
1B); however, not significantly so (p-value of 0.017, the Bonferroni
adjusted significance level is 0.0125). For both HRV 14 and HRV
16, the addition of PBMCs significantly increased IFN-a
expression (p,0.001 and p = 0.003, respectively) (Table 2).
Without the addition of PBMCs, there was no difference in IL-
28A expression between HRV 14 and HRV 16 viruses (p = 0.232)
(Table 2) 5 days p.i. After the addition of PBMCs, HRV 14
produced higher levels of IL-28A compared to HRV 16, but not
significantly so (p-value of 0.014) (Table 2). The addition of
PBMCs significantly increased IL-28A expression with HRV 14
(p = 0.001), but did not change expression of IL-28A in the HRV
16 virus (p = 0.578) (Table 2, Fig 1C). Without the addition of
PBMCs, HRV 14 produced higher levels of ENA-78 (p = 0.017),
while with the addition of PBMCs, there was no difference in levels
between the HRV 14 and HRV 16 (p = 0.208). Adding PBMCs
significantly decreased ENA-78 expression in HRV 14 infected
cells (p,0.001), but did not affect expression in HRV 16 infected
cells (p = 0.352) (Table 2, Fig 1D). Finally, there was no significant
difference in MCP-2 levels between HRV 14 and HRV 16 without
PBMCs (p = 0.502) but with PBMCs, levels of MCP-2 were higher
in HRV 14 infected cells but not significantly so (p = 0.0169)
(Table 2, Fig 1E).
While most of the HRV-associated responses were evident at all
points with greatest differences at the 5 days p.i., some were
evident at some but not all time points (Fig 1B, 1C, 1D and 1F).
For example, a much larger increase in IL-28A was detected for
HRV 16 without PBMCs at 4 days p.i. than at 5 days p.i. (Fig 1C).
We also noted donor to donor differences in the expression of
some cytokines like MCP-1, HGF, IL-1RA and RANTES not
included in the analysis above. For these cytokines, increases in
levels compared to mock-infected cells were consistent with an
HRV-associated response for some but not all PBMCs as
illustrated in Table 3. These results suggest an HRV 16-associated
response for MCP-1 and HRV 14-associated response for HGF
for PBMC 2 and PBMC 3. For IL-1RA, the values are suggestive
of an HRV 14-associated response for PMBC 2 and PBMC 3 and
HRV 16-associated response for PBMC 3. For RANTES, the
values are suggestive of an HRV 14-associated response for PBMC
1 and PBMC 2 and an HRV 16-associated response for PBMC 4.
These types of differences in responses between sources of PBMCs
are being further characterized. Next, to assess the likelihood that
experimental variability might explain some of the differences
detected, we analyzed responses in two separate experiments with
PBMCs from the same blood sample from the same donor. As
noted in Table 4, the results between experiments from the same
Table 1. HRV 14 and HRV 16-associated responses in Calu-3
cells with or without PBMCs.
Cytokine/
Chemokine Median (Range in pg/ml)
Virus Without PBMC With PBMC
FGF-Basic HRV 14 68.4 (49.9–90.3)* 52.1 (42.0–64.8)*
HRV 16 167.8 (106–201)* 146.1 (126–181)*
Uninfected 18 (9.8–23.6) 20.4 (17.5–32.3)
IL-15 HRV 14 528 (474–564)* 584 (398–967)*
HRV 16 384 (108–796) 472 (337–737)
Uninfected 210 (100–417) 226 (100–359)
IP-10 HRV 14 1559 (1006–1765)* 885 (752–900)*
HRV 16 355 (245–462)* 434 (382–553)*
Uninfected 52.4 (24.4–178) 95.8 (16.2 (172)
IL-6 HRV 14 1731 (1488–1974)* 897 (817–1038)*
HRV 16 4112 (3499–4525)* 1159 (780–1482)*
Uninfected 690 (368–817) 548 (249–734)
MIP-1b HRV 14 7.0 (5.6–8.3)** 353 (208–438)*
HRV 16 27.5 (11.9–92.9) 40.8 (16.4–77.6)
Uninfected 14.6 (9.6–41.2) 31.5 (9.8–128)
IFN-a HRV 14 61.2 (29.2–101) 1447 (1303–2375)*
HRV 16 66.8 (30.1–130) 146 (140–212)
Uninfected 74.3 (40–90.5) 154 (110–198)
MCP-2 HRV 14 8.4 (5.9–11.9) 4308 (3883–4902)*
HRV 16 5.9 (5.2–15.2) 1511 (1012–2338)*
Uninfected 8.1 (6.3–10.1) 170 (10.4–208)
IL-28A HRV 14 21.1 (12.3–22.8) 236 (196.7–250.9)*
HRV 16 32.9 (16.5–55.5) 51.7 (11.4–58.2)
Uninfected 8.2 (6.1–20.1) 18.5 (15.5–28.6)








Uninfected 8149 (5914–10656) 6941 (5086–10275)
Shown are the median values of cytokines and chemokines (pg/ml) produced in
response to HRV 14, HRV 16 and uninfected control infections at 48 hours after
the time inserts with PBMCs were added (n = 4). Significant differences in
cytokine/chemokine levels for HRV 14 and HRV 16 infected cells when
compared to uninfected controls were calculated using Wilcoxon rank sum
tests. * indicates values for HRV 14 or HRV 16 that are significantly, P,0.05,
above values for the uninfected control. ** indicates that the level of MIP-1b in
HRV 14 infected Calu-3 cells without PBMCs is significantly lower than the
uninfected controls. * P,0.05.
doi:10.1371/journal.pone.0066600.t001
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PBMCs were consistent and experiment to experiment variation
does not explain the extent of differences between HRV strains or
PBMCs. Next, to determine if the extent of virus replication
affected cytokine and chemokine levels and might explain the
differences that we saw between HRV 14 and HRV 16, we used a
higher dose of HRV 16 (2.5 or 5 MOI) which resulted in similar
levels of HRV RNA between HRV 14 (at MOI of 0.5 or 1) and
HRV 16 at the 24 hr and 48 hr time points. Although the higher
MOI for HRV 16 gave a slight increase in some cytokines, e.g.
IFN-a and MIP-1b (data not shown), it did not affect the
significance of differences between chemokine and cytokines levels
for HRV 14- and HRV 16- infected cells. Finally, to check if
factors in the virus inoculum affected our results, we purified the
viruses through 20% sucrose cushion gradient and infected Calu-3
cells with the purified viruses. We saw a similar pattern and level of
cytokine and chemokine responses between the purified and the
unpurified inoculums. Overall, the levels of each cytokine and
chemokines secreted by HRV 14, HRV 16 or uninfected control
infections without PBMCs, were within the range as given in
Table 1 suggesting that non-virus factors present in the unpurified
inoculum did not affect our results.
Discussion
Infection of respiratory epithelial cells with HRV as well as
other respiratory viruses has been shown to induce various
chemokines and cytokines that likely participate in the inflamma-
tory or immune response to infection. In this report, we describe
use of a two-chamber trans-well system to expose PBMCs to
HRV-infected respiratory epithelial cells to model the immune
response to this infection. With this system, we looked for changes
to immune responses when the infecting virus or the source of
immune cells was varied. Our data show that both virus and
source of PBMCs can affect the immune response as indicated by
changes in secreted cytokines.
A variety of cytokines and chemokines were induced by both
HRV 14 and/or HRV 16 infection that include FGF-Basic,
chemokines and cytokines like IL-6, IL-15, MCP-2, IP-10, MIP-
1b, type I IFN-a, type III IFN-l2 (IL-28A), and ENA-78. Some of
these responses have been previously noted [8,9,17]. We did not
see increases for all the cytokines or chemokines previously
reported to be induced by HRV infection. For example, we did
not see increases in IL-1, IL-8, GM-CSF, and eotaxin. The reason
for these differences is not clear, but could result from differences
in the HRVs studied, the cells used for the infection, or other
differences in methods.
The addition of PBMCs to the HRV-infected Calu-3 cells had
substantial effect on the cytokine and chemokine responses. These
changes include increases in levels of IL-28A, IFN-a, MCP-2 and
MIP-1b for one or both viruses and decreases in levels of IP-10,
IL-6, and ENA-78 for one or both viruses. Korpi-Steiner et al. also
looked at the interaction of HRV 16-infected airway epithelial cells
and human immune cells. They studied monocytes purified from
PBMCs, and used co-culture or supernatant from monocytes
exposed to HRV 16 to demonstrate a monocyte induced increase
in CXCL10 (IP-10) production by infected airway epithelial cells
[8]. Another group noted an increase in IL-6, IL-8 and RANTES
production with the addition of media from HRV exposed
PBMCs to HRV-infected airway epithelial cells [18]. Stokes et al
found that addition of monocytes to HRV 1B-infected BEAS-2B
cells did not enhance production of IL-8 or RANTES though IL-8
production was increased when infected cells were also treated
with LPS [19]. The interaction between airway epithelial cells and
human immune cells during HRV infection is likely important to
the disease process. The cytokines and chemokines induced by
HRV infection of Calu-3 cells and/or Calu-3 cells plus PBMCs
are associated with a range of functions including activation of
immune cells that are implicated in allergic responses, cell
proliferation, anti-viral activity, and pro-inflammatory and anti-
inflammatory functions.
Several findings suggest directions for future study. One
interesting finding is the difference in induction of ENA 78
between HRV 14 and HRV 16. ENA-78 has been reported to be
induced by HRV infection of BEAS-2B cells and suggested to have
a role in allergy and airway inflammation [18,20]. In the present
study, the addition of PBMCs to HRV 14-infected cells down
regulated ENA-78 production but did not affect the level of ENA-
Table 2. Virus-associated cytokine/chemokine (pg/ml) responses with and without PBMCs in Calu-3 infected cells (n = 4).
Cytokine/Chemokine Medain (Range in pg/ml) P value







IP-10 N 1559 (1006-1765) 355 (245-462) ,0.001* 0.012* 0.163
Y 885 (752-900) 434 (382-553) 0.003*
MIP-1b N 7.0 (5.6-8.3) 27.5 (11.9-92.9) 0.003* ,0.001* 0.502
Y 353 (209-439) 40.8 (16.4-77.6) 0.003*
IFN-a N 61.2 (29.2-101) 66.8 (30.1-131) 0.502 ,0.001* 0.003*
Y 1447 (1304-2375) 146 (141-212) 0.017
IL-28A N 21.1 (12.3-22.8 33.0 (16.5-55.5) 0.232 0.001* 0.578
Y 236 (197-251) 52 (11.4-58) 0.014
ENA-78 N 73733 (68961-85868) 17609 (14076-21402) 0.017 ,0.001* 0.352
Y 13862 (11461-16022) 16752 (11048-19686) 0.208
MCP-2 N 8.4 (5.9-11.8) 5.9 (5.2-15.2) 0.502 ,0.001* ,0.001*
Y 4308 (3883-4902) 1511 (1012-2338) 0.016*
‘‘N’’ indicates No PBMC exposure and ‘‘Y’’ indicates PBMC exposure. Two-factor ANOVA models were used. Four pairwise comparisons were made between HRV 14 and
HRV 16 with and without PBMCs. * indicates statistical significance at 0.0125 level.
doi:10.1371/journal.pone.0066600.t002
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78 produced by HRV 16-infected cells. Similarly, the addition of
PBMCs to HRV 14-infected cells led to increased levels of IFN-a,
MIP-1b and IL-28A and MCP-2 levels were increased in both
HRV 14 and HRV 16 infected cells when exposed to PBMCs.
Previous studies show that increases in IFN-a levels are associated
with decreased levels of ENA-78 [21]. The reduction in the levels
of some cytokines and chemokines after PBMC exposure is not
surprising since PBMCs do play an important role in regulation of
immune responses by a number of mechanisms including release
of mediators that regulates cytokine or chemokine degradation or
receptor mediated consumption of cytokines [22,23]. This in vitro
model provides a way to study the effect of production of one
cytokine on production of other as well as HRV strain differences
in cytokine and chemokine production.
Strain differences in response to HRV infection are consistent
with earlier observations. Wark and colleagues [24] measured
release of IL-6, IP-10, IFN-b and IFN-c by HRV-infected primary
bronchial epithelial cells and noted higher levels induced by recent
clinical isolates compared to laboratory passaged strains and
differences in levels between cells infected with HRVs from the
major and minor receptor groups. They also noted differences in
levels produced by infected primary bronchial epithelial cells from
asthmatic compared to non-asthmatic patients. With their system,
they did not detected differences in levels of cytokines or
chemokines induced by HRV 14 and HRV 16 [24]. Species
differences in the way the HRV 2A protease alters cell functions
has been recently reported and suggests one possible mechanism
for the differences we noted [25]. Epidemiologic studies have
shown HRV species differences in associations with asthma
exacerbations with species A HRVs showing stronger associations
than species B HRVs [26]. HRV 14 is a species B virus and HRV
16 is a species A virus. The HRV-induced responses seen in our in
vitro model provides another way to study the impact of strain
variation on disease outcome.
Responses to HRV infection by PBMCs also provides a
promising way to study patient differences that may contribute
to disease, e.g. exacerbations of asthma. Others have noted and
studied cytokine or chemokine responses during HRV infection in
respiratory specimens from patients with and without asthma. For
example, in studies of respiratory secretions, Gern et al reported
that experimental infection of allergic individuals with HRV 16
resulted in increased levels of IL-8 and granulocyte colony
stimulating factor (GCSF) [27], Miller et al found an association
between increased levels of Type III IFN-l and wheezing with
HRV infection in patients with asthma [28] and Garcia et al noted
lower levels of MCP-1 and IL-1Ra associated with increased
severity of HRV infection [29]. Groups have also looked at
cytokines and chemokines induced by exposing immune cells from
patients with asthma to HRVs. For example, Forbes et al noted
lower levels of type I and III IFN in HRV43 and 1B exposed
PBMCs from pregnant women with asthma [30], Iikura et al.
found lower levels of IFN-a and inflammatory and other cytokines
in PBMCs from patients with asthma exposed to HRV 14 [31]
and Sykes et al. found decreased type I IFN responses to HRV 16
exposed BAL cells from patients with asthma [32].
In conclusion, the results of this study show that differences in
the virus and host can lead to changes in the expression of various
cytokines produced by human airway epithelial cells and/or
PBMCs responding to HRV infection. These differences in
cytokine and chemokine expression may be associated with and
help explain differences in disease such as previously noted
differences between infections with species A and B HRVs or
between infections in children with and without asthma. This
model provides one way to study the basis for these differences and
pathogenesis of HRV disease.
Acknowledgments
We thank Theda Gibson and Katie Casper for technical assistance.
Table 3. Donor to donor difference in some cytokines secreted in HRV 14, HRV 16 and uninfected Calu-3 cells.
Cytokine/Chemokine PBMC 1 PBMC 2 PBMC 3 PBMC 4
HRV 14 HRV 16 Uninf HRV 14 HRV 16 Uninf HRV 14 HRV 16 Uninf HRV 14 HRV 16 Uninf
MCP-1 34307 154858 31706 6100 2939 6100 33717 318876 32996 8047 7308 3984
HGF ND ND ND 159 86 69 370 167 95 402 348 666
IL-1RA 1140 710 677 1702 985 543 570 585 233 924 916 1172
RANTES 346 58 135 175 56 65 498 525 418 13 56 5
Shown are the values of cytokine/chemokines (pg/ml) produced from four different PBMCs and data are for 48 hours after the time PBMCs were added to the Calu-3
cells. ND is not detected. Note values for HRV infected compared to uninfected cells suggestive of an HRV 16-associated response for MCP-1 and HRV 14-associated
response for HGF for PBMC 2 and PBMC 3. For IL-1RA, the values are suggestive of an HVR 14-associated response for PMBC 2 and PBMC 3 and HRV 16-associated
response for PBMC 3. For RANTES, the values are suggestive of an HRV 14-associated response for PBMC 1 and PBMC 2 and an HRV 16-associated response for PBMC 4.
doi:10.1371/journal.pone.0066600.t003
Table 4. Experiment to experiment variation in cytokine/
chemokine responses of PBMCs from same donor to HRV-
infected Calu-3 cells.
Cytokine/
Chemokine HRV 14 HRV 16 Uninfected
Exp 1 Exp 2 Exp 1 Exp 2 Exp 1 Exp 2
FGF-Basic 65 48 127 168 22 32
IL-15 530 483 390 356 150 127
IP-10 900 827 454 366 45 39
IL-6 900 936 1288 1383 246 307
MIP-1b 209 298 17 25 13 22
IFN-a 1433 1366 146 207 134 196
MCP-2 4644 4397 1439 1563 27 13
IL-28A 361 220 56 48 16 20
ENA-78 12087 11932 16538 12498 10255 6632
Shown are the values of cytokine/chemokines (pg/ml) produced from the same
source of PBMCs and data are for 48 hours after the time PBMCs were added to
the Calu-3 cells.
doi:10.1371/journal.pone.0066600.t004
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